Literature DB >> 3933538

Plasminogen activator in psoriatic scales is of the tissue-type PA as identified by monoclonal antibodies.

J Grøndahl-Hansen, L S Nielsen, P Kristensen, V Grøndahl-Hansen, P A Andreasen, K Danø.   

Abstract

Extracts of scale from four patients with psoriasis all contained plasminogen activator. All plasminogen activator activity was of the tissue-type (t-PA) as judged from the following criteria: all enzyme activity was inhibited by a monoclonal antibody against human t-PA, while there was no measurable inhibition by a monoclonal antibody against human urokinase-type plasminogen activator (u-PA); as determined by zymography the extracts contained one type of plasminogen activator which had an electrophoretic mobility identical to that of purified t-PA; this plasminogen activator was removed by passage through a Sepharose column coupled with a monoclonal antibody against t-PA, but not by passage through a column coupled with a monoclonal antibody against u-PA. On a molar basis the detection limit for u-PA was 10% of that of t-PA present.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3933538     DOI: 10.1111/j.1365-2133.1985.tb02076.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  Role of plasminogen activator in pemphigus vulgaris.

Authors:  J E Wilkinson; C A Smith; M M Suter; W Falchek; R M Lewis
Journal:  Am J Pathol       Date:  1989-03       Impact factor: 4.307

2.  Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis.

Authors:  B Lyons-Giordano; D Loskutoff; C S Chen; G Lazarus; M Keeton; P J Jensen
Journal:  Histochemistry       Date:  1994-02

3.  Urokinase-type plasminogen activator in endothelial cells during acute inflammation of the appendix.

Authors:  J Grøndahl-Hansen; L T Kirkeby; E Ralfkiaer; P Kristensen; L R Lund; K Danø
Journal:  Am J Pathol       Date:  1989-10       Impact factor: 4.307

4.  Tissue-type plasminogen activator in plasma from breast cancer patients determined by enzyme-linked immunosorbent assay.

Authors:  J Grøndahl-Hansen; F Bach; P Munkholm-Larsen
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.